Abstract
Neonatal herpes simplex virus (HSV) infection continues to cause significant morbidity and mortality despite advances in diagnosis and treatment. Prior to antiviral therapy, 85% of patients with disseminated HSV disease and 50% of patients with central nervous system disease died within 1 year. The advent of antiviral therapy has dramatically improved the prognosis of neonatal HSV with initially vidarabine and subsequently acyclovir increasing the survival rate of infected neonates and improving long-term developmental outcomes. More recently, polymerase chain reaction has allowed earlier identification of HSV infection and provided a quantitative guide to treatment. Current advances in the treatment of neonatal HSV infections are looking toward the role of prolonged oral suppression therapy in reducing the incidence of recurrent disease. Of concern, however, are increasing reports of acyclovir-resistant HSV isolates in patients following prolonged therapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev. 2004;17(1):1–13.
Brown ZA, Wald A, Morrow RM, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003;289:203–9.
Kimberlin DW. Neonatal HSV infections: the global picture. Herpes. 2004;11(2):31–2.
Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, Vontver LA, Corey L. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991;324:1247–52.
Brown ZA, Vontver LA, Benedetti J, Critchlow CW, Sells CJ, Berry S, Corey L. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med. 1987;317:1246–51.
Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337(8):509–15.
Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol. 1971;110(6):825–37.
Parvey LS, Ch’ien LT. Neonatal herpes simplex virus infection introduced by fetal-monitor scalp electrodes. Pediatrics. 1980;65(6):1150–3.
Johnston C, Magaret A, Selke S, Remington M, Corey L, Wald A. Herpes simplex virus viremia during primary genital infection. J Infect Dis. 2008;198(1):31–4.
Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Frenkel LM, Gruber WC et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108(2):223–9.
Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Frenkel LM, Gruber W et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108:223–9.
Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL, Alford CA. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics. 1980;66(4):495–501.
Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001;108(2):230–8.
Whitley RJ, Yeager A, Kartus P, Bryson Y, Connor JD, Alford CA et al. Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics. 1983;72(6):778–85.
Whitley RJ, Alford CA Jr, Hirsch MS, Schooley RT, Luby JP, Aoki FY et al. . Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314:144–9.
Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D et al. . A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. infectious diseases collaborative antiviral study group. N Engl J Med. 1991;324(7):444–9.
Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DW et al. . Application of the polymerase chain reactin to the diagnosis and management of neonatal herpes simplex virus disease. J Infect Dis. 1996;174:1162–7.
Malm G, Forsgren M. Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum. Arch Dis Child Fetal Neonatal Ed. 1999;81(1):F24–9.
Kimura H, Aso K, Kuzushima K, Hanada N, Shibata M, Morishima T. Relapse of herpes simplex encephalitis in children. Pediatrics. 1992;89(5 Pt 1):891–4.
Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA et al. . Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1996;174(6):1162–7.
Troendle-Atkins J, Demmler GJ, Buffone GJ. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. J Pediatr. 1993;123:376–80.
Kimura H, Futamura M, Kito H, Ando T, Goto M, Kuzushima K et al. . Detection of viral DNA in neonatal herpes simplex virus infections: Frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis. 1991;164:289–93.
Troendle-Atkins J, Demmler GJ, Buffone GJ. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. J Pediatr. 1993;123(3):376–80.
Domingues RB, Lakeman FD, Mayo MS, Whitley RJ. Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol. 1998;36:2229–34.
Kimura H, Ito Y, Futamura M, Ando Y, Yabuta Y, Hoshino Y et al. . Quantitation of viral load in neonatal herpes simplex virus infection and comparison between type 1 and type 2. J Med Virol. 2002;67(3):349–53.
Kimberlin DW, Whitley RJ. Neonatal herpes: what have we learned. Semin Pediatr Infect Dis. 2005;16(1):7–16.
Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S et al. . Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991;324(7):450–4.
Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M et al. Administration of oral acyclovir suppressive therapy following neonatal herpes simplex virus disease limited to the skin, eyes, and mouth: results of a Phase I/II tiral. Pediatr Infect Dis J. 1996;15:247–54.
Oram RJ, Marcellino D, Strauss D, Gustafson E, Talarico CL, Root AK et al. . Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. J Infect Dis. 2000;181(4):1458–61.
Levin MJ, Weinberg A, Leary JJ, Sarisky RT. Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum. Pediatr Infect Dis J. 2001;20(11):1094–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Thompson, C., Whitley, R. (2011). Neonatal Herpes Simplex Virus Infections: Where Are We Now?. In: Curtis, N., Finn, A., Pollard, A. (eds) Hot Topics in Infection and Immunity in Children VII. Advances in Experimental Medicine and Biology, vol 697. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7185-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7185-2_15
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7184-5
Online ISBN: 978-1-4419-7185-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)